tiprankstipranks
Trending News
More News >
Revive Therapeutics Ltd (TSE:RVV)
:RVV

Revive Therapeutics (RVV) Price & Analysis

Compare
129 Followers

RVV Stock Chart & Stats


---

Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.88%<0.01%99.12%
Mutual Funds
<0.01% Other Institutional Investors
99.12% Public Companies and
Individual Investors

RVV FAQ

What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <C$0.01 and its highest was C$0.04 in the past 12 months.
    What is Revive Therapeutics Ltd’s market cap?
    Revive Therapeutics Ltd’s market cap is C$10.46M.
      When is Revive Therapeutics Ltd’s upcoming earnings report date?
      Revive Therapeutics Ltd’s upcoming earnings report date is Jun 02, 2025 which is in 28 days.
        How were Revive Therapeutics Ltd’s earnings last quarter?
        Revive Therapeutics Ltd released its earnings results on Feb 28, 2025. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
          Is Revive Therapeutics Ltd overvalued?
          According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Revive Therapeutics Ltd pay dividends?
            Revive Therapeutics Ltd does not currently pay dividends.
            What is Revive Therapeutics Ltd’s EPS estimate?
            Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Revive Therapeutics Ltd have?
            Revive Therapeutics Ltd has 418,564,270 shares outstanding.
              What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
              Revive Therapeutics Ltd reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
                Currently, no hedge funds are holding shares in TSE:RVV
                ---

                Company Description

                Revive Therapeutics Ltd

                Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Mydecine Innovations Group
                Numinus Wellness
                Cybin
                Red Light Holland
                HAVN Life Sciences
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis